NewAmsterdam Pharma Co N.V.
NAMSUnited States
16 filed reports · 428 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
16 reports · Dec 2022 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 42 interim figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 8 | 1,090 | Mar 2024 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 3 | 970 | Dec 2023 to Dec 2025 |
| Current · 8-KSEC EDGAR | 2 | 2 | Jun 2024 to Dec 2024 |
| Annual · 20-FSEC EDGAR | 1 | 3 | Dec 2022 |
| Annual · 20-F/ASEC EDGAR | 1 | 515 | Dec 2022 |
| Interim · 6-KSEC EDGAR | 1 | 52 | Jun 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 256 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 174 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 18, 2026 | 547 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 170 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 99 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 111 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Feb 26, 2025 | 1 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 26, 2025 | 231 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 104 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 84 | Open |
| FY2024 Q2 | 8-K | Jun 30, 2024 | Aug 7, 2024 | 1 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 92 | Open |
Financial data
428 concepts · 2,632 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial423 concepts · 2,620 facts · Dec 2020 to Aug 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations23 · Dec 2020 to Jun 2026
- Stockholders equity (US GAAP)23 · Dec 2020 to Jun 2026
- Profit loss22 · Dec 2020 to Jun 2026
- Revenue21 · Jun 2022 to Jun 2026
- Ordinary Shares20 · Dec 2020 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value19 · Dec 2021 to Jun 2026
- Allocated share based compensation expense19 · Dec 2021 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect19 · Dec 2021 to Jun 2026
- Changes in prepayments (current and non-current) and other receivables19 · Dec 2021 to Jun 2026
- Comprehensive income net of tax19 · Dec 2021 to Jun 2026
- Depreciation depletion and amortization19 · Dec 2021 to Jun 2026
- Foreign currency transaction gain loss before tax19 · Dec 2021 to Jun 2026
- Increase decrease in accounts payable19 · Dec 2021 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities19 · Dec 2021 to Jun 2026
- Net cash provided by used in financing activities19 · Dec 2021 to Jun 2026
- Net cash provided by used in investing activities19 · Dec 2021 to Jun 2026
- Net cash provided by used in operating activities19 · Dec 2021 to Jun 2026
- Net income loss19 · Dec 2021 to Jun 2026
- Operating expenses (US GAAP)19 · Dec 2021 to Jun 2026
- Operating income loss19 · Dec 2021 to Jun 2026
- Payments to acquire productive assets19 · Dec 2021 to Jun 2026
- Research and development expense19 · Dec 2021 to Jun 2026
- Selling general and administrative expense19 · Dec 2021 to Jun 2026
- Share based compensation19 · Dec 2021 to Jun 2026
Product4 concepts · 8 facts · Jun 2022 to Jun 2023
- Menarini License3 · Dec 2022
- Revenue3 · Jun 2022 to Jun 2023
- Cost of sales1 · Dec 2022
- Sales and marketing expense1 · Dec 2022
KPI1 concepts · 4 facts · Jun 2024 to Mar 2026
- Clinical Trial Participants4 · Jun 2024 to Mar 2026
Segments
8 factsFigures broken down by business line, region, product or another axis the company reports on.
Products and services2 members · 8 facts
- Menarini License6 · Dec 2022
- Menarini license2 · Jun 2022 to Jun 2023
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.